← Back to Home

Helping mRNA Vaccines Withstand Heat: AI Identifies Formulations for Two Months of Storage at 37°C

Getting vaccines to places without refrigeration often means overcoming challenges in transit. An MIT team combined experiments with AI to keep dried mRNA vaccines biologically active after storage at high temperatures and explored vaccination using microneedle patches. Human validation and manufacturing hurdles remain before practical use.

By SURL BioNews

Whether a vaccine dose reaches the person who needs it depends not only on research and development, but also on storage conditions along the way. For mRNA, which degrades easily, the cold chain provides protection but also adds to the burden of distribution. A Massachusetts Institute of Technology (MIT) team has now identified heat-stable formulations that allow dried vaccines to retain biological activity after more than two months of storage at 37°C, providing new evidence from animal experiments for reducing reliance on the cold chain.

The study was published on September 28 in *Nature Biotechnology*. The team’s AGENT framework combines high-throughput experiments with Bayesian optimization: the algorithm uses existing results to select promising formulations for the next round of testing, then updates its predictions based on experimental feedback. Here, AI addresses how to combine excipients to protect the lipid nanoparticles (LNPs) encapsulating mRNA. The paper states that optimization took six rounds and was completed within one month.

According to MIT’s overview of the research, the team first screened nearly 50 excipients already approved for use by the U.S. Food and Drug Administration, then selected five candidate ingredients whose proportions were adjusted by the algorithm. Initial tests used mRNA encoding firefly luciferase, with the intensity of light emitted by cells indicating whether the stored mRNA could still drive protein production. This provided a measurable basis for comparing formulations and narrowed the search for subsequent animal experiments.

The study used two types of LNPs based on SM-102 and ALC-0315, respectively, representing the lipid compositions of the Moderna and Pfizer/BioNTech vaccines. The paper’s abstract reports that, after conversion to a solid state, both retained 100% biological activity as defined by the tests after more than two months of storage at 37°C. MIT also noted that the vacuum-dried formulations underwent one year of storage testing at room temperature. The two types of LNPs can use the same excipients, but require different proportions.

The ability to produce proteins after storage must be followed by confirmation that the vaccines can elicit an immune response. The paper reports that, in rodents and nonhuman primates, the antigen-specific immune responses elicited by the heat-stable solid vaccines were not inferior to those elicited by freshly prepared liquid vaccines administered by intramuscular injection. This supports the formulations’ preclinical potential, but “retaining 100% biological activity” does not mean 100% protection in humans, and immune responses cannot directly substitute for effectiveness in preventing infection.

The solid formulations also open up new possibilities for vaccine administration. The team demonstrated delivery of SARS-CoV-2 antigens using microneedle patches and observed immune responses similar to those elicited by injected vaccines. If these results can eventually be reproduced in humans, both storage and administration methods could change, allowing greater flexibility in vaccine distribution and vaccination arrangements.

The evidence remains at the preclinical stage. The abstract and research overview do not provide enough information to fully assess animal sample sizes, long-term safety, or effects in humans. Using approved excipients also does not mean that the new formulations or patches have been approved. Moving toward practical supply will require validation of safety and immune responses in humans, as well as whether consistent quality can be maintained after manufacturing is scaled up. The value of this work lies in turning the search for heat-stable formulations into a process that can be repeatedly validated, opening another path for vaccines to move beyond cold-chain constraints.

References

  1. Nature Biotechnology, Published online: 2026-09-28; | doi:10.1038/s41587-026-03330-x
  2. MIT CSAIL / MIT News
  3. PubMed / Nature Biotechnology